Physician profile
Bryan Duepner
NPI 1861912826
$3,030.15
in general payments reported to CMS, 2019-2025
28 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $223 · 2021: $12.39 · 2023: $288 · 2024: $833 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $491.85 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $327.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $180.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $165.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.40 | 2023-2025 | Jardiance |
| Amgen INC. | $130.24 | 2020-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $126.57 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $126.24 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sunovion Pharmaceuticals INC. | $123.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $119.31 | 2019 | |
| Exact Sciences Corporation | $104.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $98.36 | 2024-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.83 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $49.60 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $35.23 | 2023-2024 | Adzenys Xr-Odt |
| Edwards Lifesciences Corporation | $34.76 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $23.55 | 2025 | Rexulti |
| Depuy Synthes Sales INC. | $21.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.07 | 2024 | |
| Organon LLC | $17.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.71 | 2019 | |
| Itamar Medical INC | $15.55 | 2025 | Watchpatone |
| Tris Pharma INC | $15.34 | 2019 | |
| Nevro Corp. | $14.15 | 2024 | Senza |
| Abbott Laboratories | $13.67 | 2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $13.08 | 2024 | Quviviq |
| Esperion Therapeutics, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Duepner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.